IMUX vs NVS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IMUX and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IMUX and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Immunic, Inc. is a late-stage biotechnology company developing a portfolio of novel oral therapies aimed at neurologic and inflammatory diseases. Its lead program, vidofludimus calcium (IMU-838), is being tested in two large global Phase 3 trials, the ENSURE program, for relapsing multiple sclerosis, with thousands of patients enrolled and top-line data expected around the end of 2026. The drug is described as a first-in-class activator of the Nurr1 nuclear receptor, giving it a potential neuroprotective mechanism, combined with anti-inflammatory and anti-viral effects through selective inhibition of the DHODH enzyme.

Full IMUX guide

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

Full NVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IMUX drivers: Phase 3 multiple sclerosis readout; Differentiated mechanism.
• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is clinical trial failure: as a company whose value rests on vidofludimus calcium, a negative or ambiguous Phase 3 readout could cut the stock severely, since there is no approved product to fall back on. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IMUX if you believe its drivers more; NVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IMUX and NVS guides.

IMUX. Figures are approximate and tied to the asOf date; verify live numbers before acting. Traditional valuation metrics like P/E do not apply to a clinical-stage biotech with no earnings; the stock is valued on the probability-weighted potential of its pipeline, chiefly the Phase 3 multiple sclerosis readout, against its cash runway and share count. Value here is binary and event-driven, so the stock can move dramatically on a single data point. Treat any implied valuation as a bet on trial success, not on current fundamentals.

NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

Headline figures (approximate, Jul 2026): IMUX shows product revenue Essentially none; clinical-stage company with no approved products, lead program Vidofludimus calcium (IMU-838) in two Phase 3 relapsing-MS trials (ENSURE), key catalyst Top-line Phase 3 data expected around the end of 2026, cash position Boosted by a February 2026 private placement of roughly $187 million net; runway said to exceed twelve months; NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders.

IMUX and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IMUX and NVS exposure against your real portfolio. It is not an investment adviser.